ASX Announcements

ASX Announcements



21 November 22: LDX Signs Agreement to Raise $8m and Announces General Meeting
28 October 22: Quarterly Activities – Cash Flow Report
19 October 22: Publication of Data from DISRUPT Clinical Trial in JAMA
03 October 22: Outcome of Appeal to FDA for FebriDx
26 August 22: Lumos Diagnostics FY22 Full Year Results
23 August 22: Lumos Pilot Manufacturing to Commence in Carlsbad
8 August 22: Lumos Files Appeal to the FDA for FebriDx
8 August 22: Lumos Withdraws from Local Manufacturing Proposal
2 August 22: Lumos to Close Sarasota Facility
29 July 22: Lumos Diagnostics’ Quarterly Activity Statement and Cash Flow Report
11 July 22: FDA Decision for FebriDx
06 July 22: Trading Halt
03 July 22: Change in Substantial Holding
02 July 22: Change in Substantial Holding
02 July 22: Change in Substantial Holding
01 July 22: Security Class Reinstatement of Quotation LDXO
30 June 22: Appendix 2A
30 June 22: Change of Director’s Interest Notice – BLG
30 June 22: Change of Director’s Interest Notice – CR
30 June 22: Change of Director’s Interest Notice – SL
28 June 22: Successful Completion of Retail Entitlement Offer
27 June 22: ViraDx Receives Interim Order Authorisation in Canada
24 June 22: Change in Substantial Holding
24 June 22: Security Class Suspension from Quotation LDXO
17 June 22: Lumos Secures Development Services Contract
16 June 22: Change in Substantial Holding
15 June 22: Shareholder Webinar
14 June 22: Change in Substantial Holding
14 June 22: Ceasing to be a Substantial Holder
13 June 22: Appendix 2A
10 June 22: Letter to Ineligible Shareholders
10 June 22: Letter to Eligible Shareholders
10 June 22: Retail Entitlement Offer Opens
8 June 22: Successful Completion of Institutional Entitlement Offer
6 June 22: Operational Update and Accelerate Entitlement Offer
6 June 22: Investor Presentation
6 June 22: Target Market Determination
6 June 22: Prospectus
6 June 22: Appendix 3B
29 April 22: Quarterly Activities/Appendix 4C Cash Flow Report
11 April 22: Operational Review & Management Reorganisation
5 April 22: Notification of Cessation of Securities
1 April 22: Notification Regarding Unquoted Securities
1 April 22: Notice of Cessation of Securities
14 Mar 22: Change in Substantial Holding
1 Mar 22: Change in Substantial Holding
28 Feb 22: FebriDx Update-Brazil Market Authorisation & New Study
28 Feb 22: FY2022 Half Year Update Presentation
28 Feb 22: Lumos Diagnostics FY2022 Half Year Results
28 Feb 22: Appendix 4D & Half Year Report
16 Feb 22: Appointment of Chief Financial Officer
11 Feb 22: Release of Shares from Escrow
11 Feb 22: Final Director’s Interested Notice
11 Feb 22: Change to Lumos Board
09 Feb 22: Application for Quotation of Securities
02 Feb 22: Victorian Government Intent for Lumos Manufacturing Hub
31 Jan 22: Change in Reporting Currency
31 Jan 22: Quarterly Activities/Appendix 4C Cash Flow Report
12 Jan 22: 100+ Pharmacies in Liverpool UK Launch FebriDx Service
24 Dec 21: Section 708A Cleansing Statement
24 Dec 21: Application for Quotation of Securities
24 Dec 21: Notification Regarding Unquoted Securities
24 Dec 21: Notification Regarding Unquoted Securities
24 Dec 21: Change in Substantial Holding
22 Dec 21: Lumos Completes ViraDx™ Development and Provides FebriDx® Regulatory Update
20 Dec 21: Ceasing to be a Substantial Holder
20 Dec 21: Lumos Diagnostics Receives Initial Orders for CoviDx in Canada
18 Nov 21: Release of Shares from Escrow
11 Nov 21: Investor Communication Channels
27 Oct 21: Monthly Activities & Appendix 4C Cash Flow Report
14 Oct 21: Notification of Cessation of Securities
8 Oct 21: Update on Economic Evaluation of FebriDx
6 Oct 21: Economic Evaluation of FebriDx
30 Sept 21: Notification Regarding Unquoted Securities
27 Sept 21: Proposed Issue of Securities
27 Sept 21: Notice of Annual General Meeting & Proxy Form
22 Sept 21: U.S. FDA Deprioritizes EUA Application for CoviDx
20 Sept 21: Notice of Change of Interests of Substantial Holder
14 Sept 21: Appointment of Dr. Jerome Adams as Strategic Health Adviser
1 Sept 21: Change in Substantial Holding
30 Aug 21: FY21 Annual Report
30 Aug 21: FY21 Full Year Results Investor Presentation
30 Aug 21: FY21 Full Year Results Media Release
30 Aug 21: Corporate Governance Statement
30 Aug 21: Appendix 4G
30 Aug 21: FY21 Appendix 4E
23 Aug 21: Release of Shares from Voluntary Escrow
13 Aug 21: FY21 Financial Results Release Date
3 Aug 21: Change in substantial holding – PV
2 Aug 21: Lumos Business Momentum Continues Following ASX Listing
13 Jul 21: Notification of cessation of securities – LDX
9 Jul 21: Becoming a substantial holder – EC
8 Jul 21: Investor Presentation
6 Jul 21: Becoming a substantial holder – ACL
5 Jul 21: Becoming a substantial holder – PV
2 Jul 21: Initial Director’s Interest Notice – BLG
2 Jul 21: Initial Director’s Interest Notice – CR
2 Jul 21: Initial Director’s Interest Notice – LM
2 Jul 21: Initial Director’s Interest Notice – RS
2 Jul 21: Initial Director’s Interest Notice – SL
1 Jul 21: Becoming a substantial holder
1 Jul 21: Becoming a substantial holder – PI
1 Jul 21: Becoming a substantial holder – RPS
1 Jul 21: Media Release – Lumos Diagnostics raises $63 million in ASX IPO
1 Jul 21: Pre-quotation Disclosures
1 Jul 21: Top 20 Holders
1 Jul 21: Distribution Schedule
1 Jul 21: Securities Trading Policy
1 Jul 21: Corporate Governance Statement
1 Jul 21: Long Term Incentive Plan Rules
1 Jul 21: Employee Share Option Plan Rules
1 Jul 21: Constitution
1 Jul 21: Prospectus
1 Jul 21: Appendix 1A and Information Form and Checklist
1 Jul 21: ASX Notice – Admission to Official List


Investor-related questions? Get in touch!